Human papillomavirus genotyping of cervical uterine preneoplastic lesions in a high risk area;Detección y tipificación de virus papiloma humano en lesiones preneoplásicas de cuello uterino

Revista Medica de Chile

Volumn 138, Issue 11, 2010, Pages 1343-1350

  Jaime Lopez M ^a,e,f   Gloria Carmen Ili, G ^a,e,f   Brebi, M Priscilla ^a,e   Patricia GarciA M ^a,e   Italo Capurro, V ^a   Pablo Guzman G ^a,b   Eugenio SuaRez P ^c   Jose Manuel Ojeda F ^d   Juan Carlos Roa, S ^a,b  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b Hospital Regional de Temuco   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d UNIVERSIDAD DIEGO PORTALES   (Chile)

^e UNIVERSIDAD DE LA FRONTERA   (Chile)

^f Tecnólogo Médico   (Chile)

Author keywords

Alpha papilloma virus; Genotype; Uterine Cervical neoplasms

Indexed keywords

EID: 79551617535     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: 10.4067/s0034-98872010001200001     Document Type: Article

References (43)

1. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348 (6): 518-27.
2. Rolon PA, Smith JS, Muñoz N, Klug SJ, Herrero R, Bosch X, et al. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int J Cancer 2000; 85 (4): 486-91.
3. Brebi MP, Ili GC, López MJ, Garcia MP, Melo AA, Montenegro HS, et al. [Detection and genotyping of human papillomavirus in biopsies of uterine cervical adenocarcinoma]. Rev Med Chile 2009; 137 (3): 377-82.
4. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 2005; 10 (7): 528-38.
5. http://www.uicc.org/general-news/globocan-2008-launched.
6. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. Br J Cancer 1999; 81 (3): 554-8.
7. Aedo S, Melo A, García P, Guzmán P, Capurro I, Roa JC. Detección y tipificación de virus papilloma humano en lesiones preneoplásicas del cuello uterino mediante PCR-RFLP. Rev Med Chile 2007; 135: 167-73.
8. Roa JC, García P, Gómez J, Fernández W, Gaete F, Espinoza A, et al. HPV genotyping from invasive cervical cancer in Chile. Int J Gynaecol Obstet 2009; 105 (2): 150-3.
9. Suárez E, Prieto M, Rojas I, Fernández B, Prado R, Olfos P. Programa nacional de Cáncer Cervicouterino. Rev Chil Obstet Ginecol 2001; 66: 480-91.
10. Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, et al. Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 2004; 13 (12): 2271-6.
11. Ministerio de Salud. Guía Clínica Cáncer Cérvicouterino 21st EdSantiago: Minsal 2005.
12. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nature reviews 2007; 7 (1): 11-22.
13. Jastreboff AM, Cymet T. Role of the human papilloma virus in the development of cervical intraepithelial neoplasia and malignancy. Postgrad Med J 2002; 78 (918): 225-8.
14. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003; 16 (1): 1-17.
15. Solorza G, Ortíz A, Muñoz S, Vargas C, Vargas V. Cervical intraepithelial neoplasia. Diagnosis and treatment. Gamo 2006; 5 (4).
16. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006; 12 (17): S462-72.
17. Jenkins D. Histopathology and cytopathology of cervical cancer. Dis Markers 2007; 23 (4): 199-212.
18. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007; 25 (20): 2975-82.
19. Jung WW, Chun T, Sul D, Hwang KW, Kang HS, Lee DJ, et al. Strategies against human papillomavirus infection and cervical cancer. J Microbiol 2004; 42 (4): 255-66.
20. Janicek MF, Averette HE. Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin 2001; 51 (2): 92-114; quiz 5-8.
21. Rivera R, Aguilera J, Larraín A. Epidemiología del Virus Papiloma Humano (HPV). Rev Chil Obstet Ginecol 2002; v. 67 n. 6.
22. Petersen I, Klein F. [HPV in non-gynecological tumors]. Pathologe 2008; 29 Suppl 2: 118-22.
23. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288 (14): 1749-57.
24. Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, et al. Comparison between the Hybrid Capture II Test and an SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol 2006; 44 (5): 1733-9.
25. Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undeterminedsignificance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006; 98 (2): 92-100.
26. Guzmán P, Ili C, Rifo P, Briceño G, Araya J, Villaseca M, et al. [Prevalence of human papillomavirus genital infection among male university students]. Rev Med Chile 2008; 136 (11): 1381-9.
27. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol 2008; 46 (1): 109-17.
28. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998; 36 (10): 3020-7.
29. Melo A, Montenegro S, Hooper T, Capurro I, Roa JC, Roa I. [Human papilloma virus (HPV) typing in preneoplastic and neoplastic lesions of the uterine cervix in the IX region-Chile]. Rev Med Chile 2003; 131 (12): 1382-90.
30. McIntosh J, Sturpe DA, Khanna N. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists. J Am Pharm Assoc (2003) 2008; 48 (1): e1-13; quiz e4-7.
31. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernández-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199 (7): 926-35.
32. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-2): 1-24.
33. García P, Benavente F, Melo AA, Roa I, Roa JC. Effect of fixation on DNA quality: controlled study with five fixatives. Rev Esp Patol 2006; 39 (3): 175-9.
34. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and highthroughput identification of human papillomavirus genotypes. J Clin Microbiol 2002; 40 (3): 779-87.
35. Snijders PJ, van den Brule AJ, Jacobs MV, Pol RP, Meijer CJ. HPV DNA detection and typing in cervical scrapes. Methods Mol Med 2005; 119: 101-14.
36. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89 (1): 101-5.
37. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (5): 1157-64.
38. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366 (9490): 991-8.
39. Pretet JL, Jacquard AC, Carcopino X, Monnier-Benoit S, Averous G, Soubeyrand B, et al. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study. Int J Cancer 2008; 122 (2): 424-7.
40. Bhattarakosol P, Lertworapreecha M, Kitkumthorn N, Triratanachai S, Niruthisard S. Survey of human papillomavirus infection in cervical intraepithelial neoplasia in Thai women. J Med Assoc Thai 2002; 85 Suppl 1: S360-65.
41. Esmaeili M, Bonyadi M, Dastranj A, Alizadeh M, Melli MS, Shobeiri MJ. HPV typing in women with cervical precancerous and cancerous lesions in northwestern Iran. Gynecol Obstet Invest 2008; 66 (1): 68-72.
42. Santos C, Muñoz N, Klug S, Almonte M, Guerrero I, Alvarez M, et al. HPV types and cofactors causing cervical cancer in Peru. Br J Cancer 2001; 85 (7): 966-71.
43. García P, Benavente F, Melo A, Roa I, Roa J. Effect of fixation on DNA quality: controlled study with five fixatives. Rev Esp Patol 2006; 39: 175-9.